EGFR and neoplasm: The A/NSCLC patients, one with 38.4% EGFR+ and 45.3% CXCR4+ serum sEVs and the other with 23% EGFR+ and 61.6% CXCR4+ serum sEVs both showed high levels of EGFR and CXCR4 in the primary tumor biopsy (Figure 3D and Supplementary Figure S9B).